Physician profile
Anna K Evatt
NPI 1508331968
$2,263.51
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $495 · 2023: $910 · 2024: $562 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $559.59 | 2021-2023 | Amplatzer Amulet, Mitraclip |
| Medtronic, INC. | $339.82 | 2022-2024 | Onyx Frontier, Corevalve Evolut R |
| Edwards Lifesciences Corporation | $278.57 | 2023-2024 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.00 | 2023-2025 | Lifevest |
| Abiomed | $177.42 | 2024 | Impella |
| Stryker Corporation | $152.55 | 2025 | Artix Mt, Flowtriever |
| Angiodynamics, INC. | $138.01 | 2022 | |
| Boston Scientific Corporation | $133.78 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $98.31 | 2023 | Camzyos |
| Amgen INC. | $62.17 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $32.88 | 2023 | Xarelto |
| Pfizer INC. | $21.27 | 2024 | |
| Chiesi USA, INC. | $18.61 | 2024 | Kengreal |
| Novartis Pharmaceuticals Corporation | $18.21 | 2023 | |
| Impulse Dynamics (USA) INC. | $13.32 | 2023 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Evatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.